openPR Logo
Press release

New Drug Development and Government Support to Root Out Hypoparathyroidism

12-21-2018 11:45 AM CET | Advertising, Media Consulting, Marketing Research

Press release from: Future Market Insights

New Drug Development and Government Support to Root Out

The global hypoparathyroidism treatment landscape that only gained much significance post the FDA approval of Natpara in 2015, is projected grow at a rather robust CAGR of approximately 8% through 2026. As per a recent in-depth analysis by Future Market Insights (FMI), the valuation of global hypoparathyroidism treatment market is expected to stand at US$ 663.7 Million in 2019. Although the growth rate is expected to showcase similar trends, the global hypoparathyroidism treatment market is still in its infancy, with most of the treatment options in various phases of clinical programs.

View complete report: https://www.futuremarketinsights.com/reports/hypoparathyroidism-treatment-market

“The global hypoparathyroidism treatment market holds the potential to exceed the US$ 1.1 Billion mark by 2026, in terms of revenue. The treatment landscape for hypoparathyroidism—a rare endocrine disorder, characterized by high phosphate and low calcium levels, during low or inappropriately normal PTH level—will mostly be driven by increasing incidences of thoracic surgeries and cancer combined with Rising screening rates of thyroid diseases. Moreover, considering the rarity, hypoparathyroidism was classified as an orphan disease in European Union and United States. Considering which, favorable government schemes relating to orphan drug combined with tax incentives such as tax credits for qualified clinical trials and market exclusivity upon regulatory approval are some expected to translate into high return on investment for companies innovating drugs in hypoparathyroidism treatment market”, explains a senior analyst.

A Comprehensive Analysis of the Pipeline Clinical Programs for Hypoparathyroidism Treatment by FMI, Reveals:

There are around 47 ongoing clinical programs, globally, at different stages of development, wherein, 43 are interventional studies and 19 involve API with high potential market equity.

Request Report TOC @ https://www.futuremarketinsights.com/askus/rep-gb-7857

Most of these clinical programs are aimed at evaluating the efficacy of different treatment lines for hypoparathyroidism treatment, involving Calcitriol, calcium supplements, and magnesium.

Moreover, since hypoparathyroidism is the state of decreased secretion or activity of parathyroid hormone (PTH), close to 12 such clinical trials are focused on parathyroid hormone.

Of the total active clinical programs, phase III and phase IV clinical trials, collectively account for approximately 37.3 percent.

FMI, in its market study on hypoparathyroidism treatment also indicates that nearly 7 percent clinical programs stand terminated, suspended or withdrawn given their side-effects and failed efficacy.

Although approximately 45 percent clinical trials stand completed, most of the trials do not meet or partially meet the hypoparathyroidism treatment guidelines set by regulatory authorities.

Of the 47 percent active clinical trials, Shire continues to remain the leader in Hypoparathyroidism treatment clinical space with over 7 such active programs, followed by Entera Bio Ltd.

North America, accounting for nearly 57 percent leads the clinical trials landscape for hypoparathyroidism treatment, followed by Europe at 29 percent, as in 2017.

Request for sample report: https://www.futuremarketinsights.com/reports/sample/rep-gb-7857

Natpara Holds Approximately $2 Billion Market Opportunity, Reveals FMI

Considering a significant patient pool for hypoparathyroidism treatment and extremely low competition, Natpara is projected to showcase maximum revenue opportunity, with its demand expanding at magnificent CAGR of 145.8 percent, in the last few years.

Ever since its approval in 2015, Natpara has demonstrated a year-on-year growth of 72.8 percent through 2017

Despite labeling restrictions (Natpara Risk Evaluation and Mitigation Strategy (REMS) Program), considering Natpara’s side effects including possible bone cancer (osteosarcoma) and high blood calcium (hypercalcemia), the U.S. currently accounts for 99 % of the total Natpara sales. In EU, sales of Natpara reached US$ 109.8 Million, in H1 2018—both the regions representing substantial revenue growth opportunities.

The bioengineered replacement biologic is also projected to drive significnat adoption of drug titration based on individual cases, translating into personalized medicines.

Hypoparathyroidism Treatment Market Showcases a Fairly Consolidated Landscape

Largely dominated by branded drug manufacturers, the competition in Hypoparathyroidism Treatment Market is projected to remain low through the forecast period of 2018-2026. Key leaders including EnteraBio Ltd., Shire-NPS Pharmaceuticals, Inc., and Teva Pharmaceutical Industries Ltd. account for nearly 50 percent market share, with a key focus on developing novel treatment options for hypoparathyroidism. Apart from new product innovations, key players are also expected to take the ‘strategic acquisitions to expand global presence combined with increasing distribution channel’ route to reach untreated patient pool. In Asia, India accounts for the highest hypoparathyroidism-related mortality incidences, compared to any other region, arising from lack of sufficient screening and treatment lines. However, on the other hand, large unmet treatment needs combined with long clinical trials, will translate into patients opting for alternative medications available in the form of calcium and vitamin generics, thereby increasing the buyer advantage.

Insights Drawn From Segmentation Analysis of Hypoparathyroidism Treatment Market

While US dominates the hypoparathyroidism treatment landscape with 86 percent market share considering reasons mentioned, Asia Pacific is also projected to witness strong growth.

In terms of drug class, calcium supplements will remain the most preferred, with 38 percent market share. PTH will also showcase substantial growth rate.

On the basis of route of administration, parenteral method will remain the fastest growth segment, compared to oral methods.

Sales of hypoparathyroidism treatment drugs through retail pharmacies will generate maximum revenue, followed by hospital pharmacies.

Future Market Insights is the premier provider of market intelligence and consulting services, serving clients in over 150 countries. FMI is headquartered in London, the global financial capital, and has delivery centres in the U.S. and India.

FMI’s research and consulting services help businesses around the globe navigate the challenges in a rapidly evolving marketplace with confidence and clarity. Our customised and syndicated market research reports deliver actionable insights that drive sustainable growth. We continuously track emerging trends and events in a broad range of end industries to ensure our clients prepare for the evolving needs of their consumers.

CONTACT:

Future Market Insights
U.S. Office
616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989,
United States
T: +1-347-918-3531
F: +1-845-579-5705
Email: sales@futuremarketinsights.com
Web: https://www.futuremarketinsights.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release New Drug Development and Government Support to Root Out Hypoparathyroidism here

News-ID: 1455834 • Views: 171

More Releases from Future Market Insights

Hormone Replacement Therapy Market COVID-19 Impact and Global Analysis by Produc …
Hormone Replacement Therapy is any form of hormone therapy where in the patient, in course of medical treatment, receives hormones, either to supplement a lack of naturally occurring hormones, or to substitute other hormones for naturally occurring hormones. Menopause, is the time in most women's lives when menstrual periods stop permanently, and the woman is no longer able to have children. Menopause typically occurs between 45 and 55 years of age.
Critical Care Information Systems Market Key Players- Affiliated Computer Servic …
Critical care information systems are used to help manage the large amount of data generated in an intensive care unit every day. Obtaining, synchronizing, assimilating, and evaluating patient data is very difficult because of incompatibilities among monitoring equipment, the absence of standard data formatting and proprietary limitations from industry. The intensive care units are a specialized section of a hospital containing the equipment, medical and nursing staff, monitoring and life
Paper Cores Demand Catalyzes amid High Emphasis on Circular Economy: FMI Study
The global packaging industry has made remarkable progress in recent years, with numerous innovations and technological advances prioritized. Particular emphasis is placed on ensuring sustainability and the spread of the circular economy. Reliable benefits have been obtained in reducing the generation of municipal solid waste. Future Market Insights is a recently published research report that incorporates historical analysis from 2015 to 2019 and future assessments from 2020 to 2030 to
Endometrial Cancer Treatment Market Key Players- R-Pharm-US LLC., Bristol-Myers …
Endometrial cancer or uterine cancer is one of the most common gynecological cancers and 2.8% of women are diagnosed with the endometrial cancer at some point in their lives. According to National Cancer Institute statistics, in 2015 endometrial cancer contributed to 1.8% of all cancers and 3.6% of all new cancer cases were diagnosed as endometrial cancer. Early detection of endometrial cancer helps in the selection of proper treatment options.

All 5 Releases


More Releases for Natpara

Parathyroid Hormone | Global Market 2019 Study and Analysis | Abbott Laboratorie …
Los Angeles, United State, May 20, 2019, - The research study presented here is an intelligent take on the global Parathyroid Hormone Market that explains important aspects such as competition, segmentation, and regional growth in great detail. Accuracy and preciseness are two of the key features of the report that reflect its authenticity. The authors of the report have focused on SWOT analysis, Porter’s Five Forces analysis, and PESTLE analysis of
Hypoparathyroidism Treatment Market Analysis by 2028 | Shire-NPS Pharmaceuticals …
The global hypoparathyroidism treatment landscape that only gained much significance post the FDA approval of Natpara in 2015, is projected grow at a rather robust CAGR of approximately 8% through 2026. As per a recent in-depth analysis by Future Market Insights (FMI), the valuation of global hypoparathyroidism treatment market is expected to stand at US$ 663.7 Million in 2019. Although the growth rate is expected to showcase similar trends, the global hypoparathyroidism
Incidence of cancer are expected to be the prime factors driving the growth of t …
The global hypoparathyroidism treatment landscape that only gained much significance post the FDA approval of Natpara in 2015, is projected grow at a rather robust CAGR of approximately 8% through 2026. As per a recent in-depth analysis by Future Market Insights (FMI), the valuation of global hypoparathyroidism treatment market is expected to stand at US$ 663.7 Million in 2019. Although the growth rate is expected to showcase similar trends, the
Parathyroid Hormone Report on Global and United States Market Status 2017-2022 a …
Qyresearchreports include new market research report "2017-2022 Parathyroid Hormone Report on Global and United States Market, Status and Forecast, by Players, Types and Applications" to its huge collection of research reports. This report studies the Parathyroid Hormone market status and outlook of global and United States, from angles of players, regions, product types and end industries; this report analyzes the top players in global and United States market, and splits the
Research Delivers Insight into the Global Outlook for Hypoparathyroidism Treatme …
Hypoparathyroidism is a conditions when parathyroid glands does not work properly for creation of hormone. Hypoparathyroidism is caused by many reasons as some are like injury or removal of parathyroid glands, DiGeorge syndrome a genetic disorder, autoimmune disease, cancer radiation treatment, and by low magnesium level. The function of parathyroid hormone is to regulate the level of phosphorous and calcium in the blood. The Symptoms of hypoparathyroidism occurs when the
Hypoparathyroidism Treatment Market: Advanced Technologies, Growth & Opportuniti …
Hypoparathyroidism is a conditions when parathyroid glands does not work properly for creation of hormone. Hypoparathyroidism is caused by many reasons as some are like injury or removal of parathyroid glands, DiGeorge syndrome a genetic disorder, autoimmune disease, cancer radiation treatment, and by low magnesium level. The function of parathyroid hormone is to regulate the level of phosphorous and calcium in the blood. The Symptoms of hypoparathyroidism occurs when the